Cargando…
Predictive Biomarkers of Bacillus Calmette-Guérin Immunotherapy Response in Bladder Cancer: Where Are We Now?
The most effective therapeutic option for managing nonmuscle invasive bladder cancer (NMIBC), over the last 30 years, consists of intravesical instillations with the attenuated strain Bacillus Calmette-Guérin (the BCG vaccine). This has been performed as an adjuvant therapeutic to transurethral rese...
Autores principales: | Lima, Luís, Dinis-Ribeiro, Mário, Longatto-Filho, Adhemar, Santos, Lúcio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420223/ https://www.ncbi.nlm.nih.gov/pubmed/22919375 http://dx.doi.org/10.1155/2012/232609 |
Ejemplares similares
-
Bacillus Calmette–Guérin Immunotherapy for Cancer
por: Cardillo, Fabíola, et al.
Publicado: (2021) -
Predictive biomarkers of response to bacillus Calmette‐Guérin immunotherapy and bacillus Calmette‐Guérin failure for non‐muscle invasive bladder cancer
por: Wang, Ziting, et al.
Publicado: (2022) -
Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer
por: Rachakonda, Tara, et al.
Publicado: (2017) -
Bacillus Calmette-Guérin in the management of superficial bladder cancer
por: Kapoor, Rakesh, et al.
Publicado: (2008) -
Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer
por: Liu, Yuqing, et al.
Publicado: (2019)